Genmab — Juni 2018
-
99,3 %
-
JV - nej median PFS ikke nået, se side 11 http://ir.genmab.com/static-files/883e0329-61cc-418c-8703-cf8cc8e010f1
-
Resten er gemt, så der stadig er råd til en juicebrik, hvis alt andet fejler
-
Jep - har set den. Men ifht cut off på 27 måneder på den graf er vi vel minimum ude i 33 måneder. Data er i hvert fald 6 måneder gamle
-
Som GEN angiver er det ASH og fda application data i grafen
-
OK. Men der ikke annonceret at median PFS er nået. Måske nye data på ESMO?
-
Det må da også give onkologerne lidt hovedbrud, at Alcyone tilsyneladende performer bedre end den nuværende backbone 1st Line behandling i previously untreated
-
Ptjaaah, der var jo ikke noget på asco. Måske den info skal bruges ifm forhandlinger efter ema godkendelse?
-
this is in spanish, maybe @bibob can help, Informe de Posicionamiento Terapéutico de daratumumab (Darzalex
) en mieloma múltiple https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-daratumumab-Darzalex-mieloma-multiple-MM.pdf -
and i am just going to repost the article from Plesner from yesterday, as i think most will have missed it , Daratumumab for the Treatment of Multiple Myeloma , https://www.frontiersin.org/articles/10.3389/fimmu.2018.01228/full
-
"If further substantiated that an implication may be that daratumumab should be part of any anti-myeloma treatment. Given the pleiotropic effects of daratumumab, it is in fact difficult to imagine how a myeloma patient can become truly refractory to daratumumab."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind